300841 康华生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.7716.29611.45315.45520.817
总资产报酬率 ROA (%)0.6915.4729.68012.85817.776
投入资产回报率 ROIC (%)0.7475.98610.83214.66520.247

边际利润分析
销售毛利率 (%)90.97992.03594.20393.45393.562
营业利润率 (%)17.21022.30632.63436.55547.383
息税前利润/营业总收入 (%)16.66721.90932.01935.88546.507
净利润/营业总收入 (%)15.86718.87527.84132.28241.339

收益指标分析
经营活动净收益/利润总额(%)109.460103.895119.201107.69097.339
价值变动净收益/利润总额(%)6.6120.716-12.598-5.4448.322
营业外收支净额/利润总额(%)-0.460-0.049-0.056-0.456-0.250

偿债能力分析
流动比率 (X)7.8895.7434.3933.8973.507
速动比率 (X)7.4005.4234.0813.6433.256
资产负债率 (%)8.74211.77914.40316.51617.122
带息债务/全部投入资本 (%)0.6483.5735.0135.0864.473
股东权益/带息债务 (%)15,191.6132,674.0321,887.3911,859.1922,130.120
股东权益/负债合计 (%)1,043.891748.965594.323505.461484.054
利息保障倍数 (X)-35.884-56.689-53.596-71.230-61.344

营运能力分析
应收账款周转天数 (天)631.243390.035340.596307.828264.297
存货周转天数 (天)843.278616.223759.877570.290500.834